TransMedics Group, Inc. ($TMDX) reported its third-quarter earnings for 2024, revealing a revenue of $108.8 million, which represents a 64% increase year-over-year but fell short of analyst estimates of $114.99 million. The company's earnings per share (EPS) was $0.12, below the expected $0.29, and net income was $4.2 million compared to the estimated $11.7 million. The gross margin also declined to 56%, down from 61% in the same quarter last year. Following the earnings report, the stock experienced a significant sell-off, dropping approximately 30% in after-hours trading. Despite the disappointing results, the company maintained its annual revenue guidance for 2024, projecting revenues between $425 million and $445 million, indicating a growth rate of 76% to 84% over 2023. The increase in transplantations performed was noted as up 130% year-over-year, showcasing the company's ongoing hyper-growth potential in the healthtech sector.